Matches in Wikidata for { <http://www.wikidata.org/entity/Q86303390> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q86303390 description "clinical trial" @default.
- Q86303390 description "ensayu clínicu" @default.
- Q86303390 description "klinisch onderzoek" @default.
- Q86303390 description "клінічне випробування" @default.
- Q86303390 name "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 name "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 type Item @default.
- Q86303390 label "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 label "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 prefLabel "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 prefLabel "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION" @default.
- Q86303390 P1132 Q86303390-4E291C08-4397-4A40-88E5-14436BE11BAB @default.
- Q86303390 P1476 Q86303390-02B48501-EA5A-47C3-9ABD-9DC073FA83BD @default.
- Q86303390 P17 Q86303390-14B657DD-3BCC-4B7B-A383-1BA5BC903C27 @default.
- Q86303390 P1813 Q86303390-3F75E8F3-3B9E-4F3D-B986-5B75B06D78FE @default.
- Q86303390 P2899 Q86303390-CFEAB0E0-1616-4864-8C7B-DF192092A674 @default.
- Q86303390 P3098 Q86303390-8E20CDC8-22B6-48A1-A135-223872C16C5B @default.
- Q86303390 P31 Q86303390-888C42BB-5481-4273-B44D-B819C2277027 @default.
- Q86303390 P4844 Q86303390-8E4B90AF-5C10-43A1-AD8F-6BD6CF426AE3 @default.
- Q86303390 P580 Q86303390-8EC8669C-8539-446D-AF32-993DCA67BABE @default.
- Q86303390 P582 Q86303390-D1179285-40CA-420A-9BBF-3D670210FFA9 @default.
- Q86303390 P6099 Q86303390-9A3FD043-D4BB-4F87-9350-DFF824D2F822 @default.
- Q86303390 P767 Q86303390-27633E4B-42A6-4BC6-A23E-961A7BF69A7B @default.
- Q86303390 P8363 Q86303390-29F1838D-2FA3-4CA5-A5F7-FCF8A38DC180 @default.
- Q86303390 P1132 "+55" @default.
- Q86303390 P1476 "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)" @default.
- Q86303390 P17 Q16 @default.
- Q86303390 P1813 "DOMINATION" @default.
- Q86303390 P2899 "+18" @default.
- Q86303390 P3098 "NCT04262375" @default.
- Q86303390 P31 Q30612 @default.
- Q86303390 P4844 Q19904005 @default.
- Q86303390 P580 "2020-03-02T00:00:00Z" @default.
- Q86303390 P582 "2023-03-02T00:00:00Z" @default.
- Q86303390 P6099 Q42824440 @default.
- Q86303390 P767 Q731938 @default.
- Q86303390 P8363 Q78089383 @default.